8-K

United States

Securities and Exchange Commission

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 18, 2009

MTS Medication Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-31578	59-2740462
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2003 Gandy Boulevard North, Suite 800, St. Petersburg, Florida	33702
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (727) 576-6311

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On December 18, 2009, MTS Medication Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that its stockholders voted to approve the Agreement and Plan of Merger, dated as of August 7, 2009 (the “Merger Agreement”), with MedPak Holdings, Inc., an affiliate of Excellere Partners, and MedPak Merger Sub, Inc., a wholly owned subsidiary of MedPak Holdings, Inc. The press release also announced that the transactions contemplated by the Merger Agreement are expected to be consummated on or about December 22, 2009, subject to the satisfaction of certain customary closing conditions. A copy of the press release is attached as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT	DESCRIPTION
99.1	Press Release, dated December 18, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	MTS Medication Technologies, Inc. (Registrant)
Date: December 18, 2009	By:	/s/    MICHAEL P. CONROY
		Michael P. Conroy Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

MTS Medication Technologies, Inc. Stockholders Approve Merger Agreement

NEWS RELEASE

Corporate Contact   MTS Medication Technologies, Inc. Michael P. Conroy, CFO Phone: 727-576-6311, Ext. 1464 Fax: 727-579-8067 ir@mts-mt.com Investor Relations   Porter, LeVay & Rose, Inc. Michael Porter, Investor Relations Phone: 212-564-4700 Fax: 212-244-3075 plrmail@plrinvest.com

ST. PETERSBURG, Fla. – December 18, 2009 – MTS Medication Technologies, Inc. (NasdaqCM:MTSI), an international provider of medication adherence packaging systems, announced that at the Company’s special meeting held today, the stockholders of the Company voted to adopt the Agreement and Plan of Merger, dated as of August 7, 2009, by and among the Company, MedPak Holdings, Inc., an affiliate of Excellere Partners, LLC, and MedPak Merger Sub, Inc., a wholly owned subsidiary of MedPak Holdings, Inc. The transaction is expected to be completed on or about December 22, 2009, subject to the satisfaction of certain customary closing conditions. Under the terms of the merger agreement, the Company’s stockholders will be entitled to receive $5.75 per share in cash, without interest.

About the Company

Founded in 1984, MTS Medication Technologies (www.mts-mt.com) is an international provider of medication adherence packaging systems designed to improve medication dispensing and administration. MTS manufactures automated packaging machines and related consumables for prescription medications and nutritional supplements. MTS serves approximately 8,000 pharmacies worldwide.

About Excellere Partners

Excellere Partners (www.excellerepartners.com) is a Denver-based private equity firm that specializes in completing recapitalization transactions with middle-market companies.

This press release contains forward-looking statements within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include statements regarding the completion of the transaction. These statements are based on the current expectations of management of MTS Medication Technologies, Inc. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this document. For example, among other things, conditions to the closing of the transaction may not be satisfied and the transaction may be subject to unexpected delays. Additional factors that may affect the future events or results of MTS Medication Technologies are set forth in its filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Unless required by law, MTS Medication Technologies, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.